MET and non-small cell lung carcinoma: Here, we sought to assess the efficacy of combining MET with immunotherapeutic agents in LKB1-mutant NSCLC tumors and in various subsets of PBMCs, specifically lymphocytes and monocytes isolated from treatment-naive NSCLC patients.